Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.73 |
| ▸ | ADRB1 | P08588 | 18/20 | 0.73 |
| ▸ | DRD3 | P35462 | 2/20 | 0.73 |
| ▸ | DRD2 | P14416 | 13/20 | 0.72 |
| ▸ | ADRA1D | P25100 | 13/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799656 | 1.00 | ADRB2 (0.73) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| Hydrochloric Acid SCHEMBL1801633 | 0.99 | ADRB2 (0.72) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| Hydrochloric Acid SCHEMBL1801631 | 0.99 | ADRB2 (0.72) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL12619771 | 0.90 | ADRB2 (0.68) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL4717642 | 0.87 | ADRB2 (0.60) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL14423748 | 0.85 | ADRB2 (0.82) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL14423678 | 0.85 | ADRB2 (0.82) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL1803689 | 0.84 | ADRB2 (0.85) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL1803600 | 0.84 | ADRB2 (0.98) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL1800511 | 0.84 | ADRB2 (0.98) | ADRB2ADRB1DRD3DRD2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951954-B2 | Bezothiazol derivatives as Beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | claimed |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | claimed |
| US-7951954-B2 | Bezothiazol derivatives as Beta2 adrenoreceptor agonists | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062259-A1 | Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885DRD3 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.